Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: RPL15

Summary for RPL15

Gene information	Gene symbol	RPL15
	Ensembl ID	ENSG00000174748
	Entrez ID	6138
	Gene name	ribosomal protein L15
	Synonyms	EC45\|L15\|RPL10\|RPLY10\|RPYL10
	Gene type	protein_coding
	UniProtAcc	P61313

Top

Dataset with differentially expressed gene: RPL15

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	0.50714	6.53e-14
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	-0.296836	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	0.260395	3.70e-03
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.358496	2.53e-12
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.427374	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.320789	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.353655	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.295571	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.399285	1.51e-26
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.881472	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.338015	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	-0.258881	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Plasma cells	-0.36713	1.26e-08
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	-0.257251	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	cDCs	0.289399	1.39e-10
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.993073	3.51e-29
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	0.387672	5.18e-09
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.333478	7.63e-06
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.364074	1.54e-05
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.461237	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Erythrocytes	-0.265689	7.19e-08
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	-0.760749	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	-0.257849	1.77e-03
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.8278	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.755758	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.308508	3.31e-28
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	0.420205	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.432671	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.594541	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-1.91538	1.05e-10
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	0.547669	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	0.388357	1.46e-10
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD4+ T cells	0.355923	6.60e-03
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	0.39848	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.534381	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.397737	4.36e-35
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	-0.320297	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	0.482301	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	0.403718	0.00e+00

Top

Expression of RPL15 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to RPL15

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating RPL15

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
RPL15	hsa-miR-616-5p	99.6827	NM_001253384
RPL15	hsa-miR-373-5p	99.6827	NM_001253384
RPL15	hsa-miR-371b-5p	99.6827	NM_001253384
RPL15	hsa-miR-1273h-5p	96.4522	NM_001253384
RPL15	hsa-miR-3613-3p	96.1691	NM_001253384
RPL15	hsa-miR-6780a-5p	95.6838	NM_001253384
RPL15	hsa-miR-7106-5p	93.591	NM_001253384
RPL15	hsa-miR-520b-5p	93.5549	NM_001253384
RPL15	hsa-miR-519a-2-5p	93.5549	NM_001253384
RPL15	hsa-miR-3689a-3p	93.1313	NM_001253384
RPL15	hsa-miR-6779-5p	93.1313	NM_001253384
RPL15	hsa-miR-3689b-3p	93.1313	NM_001253384
RPL15	hsa-miR-3689c	93.1313	NM_001253384
RPL15	hsa-miR-30b-3p	93.1313	NM_001253384
RPL15	hsa-miR-4728-5p	92.0948	NM_001253384
RPL15	hsa-miR-6513-5p	91.2918	NM_001253384
RPL15	hsa-miR-548s	90.871	NM_001253384
RPL15	hsa-miR-6780b-5p	90.419	NM_001253384
RPL15	hsa-miR-4725-3p	90.419	NM_001253384
RPL15	hsa-miR-92b-3p	90.089	NM_001253380
RPL15	hsa-miR-92a-3p	90.089	NM_001253380
RPL15	hsa-miR-32-5p	90.089	NM_001253380
RPL15	hsa-miR-4271	89.4448	NM_001253384
RPL15	hsa-miR-372-5p	88.8046	NM_001253384
RPL15	hsa-miR-371a-5p	88.8046	NM_001253384
RPL15	hsa-miR-367-3p	88.3829	NM_001253380
RPL15	hsa-miR-25-3p	88.3829	NM_001253380
RPL15	hsa-miR-363-3p	88.3829	NM_001253380
RPL15	hsa-miR-3926	87.6299	NM_001253384
RPL15	hsa-miR-5683	87.0651	NM_001253384
RPL15	hsa-miR-6785-5p	86.484	NM_001253384
RPL15	hsa-miR-1179	86.3943	NM_001253380
RPL15	hsa-miR-3158-5p	86.3283	NM_001253380
RPL15	hsa-miR-6799-5p	85.8835	NM_001253384
RPL15	hsa-miR-3611	85.3734	NM_001253380
RPL15	hsa-miR-4325	83.5098	NM_001253380
RPL15	hsa-miR-4477a	82.9937	NM_001253380
RPL15	hsa-miR-627-3p	81.9254	NM_001253380
RPL15	hsa-miR-138-1-3p	81.5496	NM_001253384
RPL15	hsa-miR-6730-5p	81.1356	NM_001253380
RPL15	hsa-miR-149-3p	80.8183	NM_001253384
RPL15	hsa-miR-6883-5p	80.8183	NM_001253384
RPL15	hsa-miR-450a-1-3p	80.5852	NM_001253384

Page: 1

Top

Motifs and transcription factors (TFs) regulating RPL15

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
RPL15	taipale_tf_pairs__MEIS1_ELF1_NTGCCGGAAGTN_CAP_repr	ELF1; MEIS1 (directAnnotation).
RPL15	cisbp__M02645	ETS1 (directAnnotation).
RPL15	taipale_tf_pairs__FOXO1_ELK3_RCCGGAWGTKKW_CAP	ELK3; FOXO1 (directAnnotation).
RPL15	dbtfbs__GMEB1_K562_ENCSR928KOR_merged_N1	GMEB1 (directAnnotation).
RPL15	taipale_tf_pairs__ETV5_EOMES_TNRCACCGGAWN_CAP	EOMES; ETV5 (directAnnotation).
RPL15	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	ELF2 (directAnnotation).
RPL15	taipale_tf_pairs__ELK1_EOMES_TNRCACCGGAAGN_CAP	ELK1; EOMES (directAnnotation).
RPL15	taipale_tf_pairs__HOXB2_ELF1_SMGGAAGTMRTTA_CAP	ELF1; HOXB2 (directAnnotation).
RPL15	taipale_tf_pairs__ETV2_HES7_RSCGGAANNNNNNNCACGTGNN_CAP_repr	ETV2; HES7 (directAnnotation).
RPL15	metacluster_138.2	ELF1; ELF2; ELF4; ELK1; ELK1; ELK1; ELK1; ELK3; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ELK4; ERF; ERG; ERG; ERG; ERG; ETS1; ETS1; ETS2; ETS2; ETV1; ETV1; ETV1; ETV2; ETV3; ETV4; ETV5; ETV5; FEV; FLI1; FLI1; GABPA; GABPA; KMT2B; SPDEF; SPDEF; SPDEF; ZBTB11; ZNF518A; ZNF580 (directAnnotation). ELF1; ELF2; ELF4; ELK1; ELK1; ELK3; ELK4; ERG; ETS1; ETS2; ETV1; ETV2; ETV3; ETV4; ETV5; FEV; FLI1; FLI1; GABPA; SPDEF; SPDEF (inferredBy_Orthology).
RPL15	taipale_tf_pairs__ATF4_TEF_RNMTGATGCAATN_CAP	ATF4; TEF (directAnnotation).
RPL15	taipale_tf_pairs__ATF4_CEBPD_NGATGATGCAATNN_CAP	ATF4; CEBPD (directAnnotation).
RPL15	taipale_tf_pairs__ATF4_CEBPB_NNATGAYGCAAYN_CAP	ATF4; CEBPB (directAnnotation).
RPL15	kznf__ZNF594_Schmitges2016_RCADE	ZNF594 (directAnnotation).
RPL15	transfac_pro__M04617	ZBTB7A (directAnnotation).
RPL15	metacluster_3.5	KLF14; KLF15; KLF15; KLF16 (directAnnotation).
RPL15	taipale_cyt_meth__ZNF460_NRMCGCCCCCCGN_eDBD_meth	ZNF460 (directAnnotation).
RPL15	transfac_pro__M07387	ZBTB7A (directAnnotation).
RPL15	transfac_pro__M07436	WT1 (directAnnotation).
RPL15	transfac_pro__M07461	KLF1; KLF10; KLF11; KLF12; KLF13; KLF15; KLF16; KLF17; KLF2; KLF3; KLF4; KLF5; KLF6; KLF7; KLF8; KLF9 (directAnnotation).
RPL15	transfac_pro__M00716	ZBTB14 (directAnnotation).
RPL15	hdpi__HIP2	UBE2K (directAnnotation).
RPL15	taipale_tf_pairs__GCM1_SPDEF_RTGNKGGCGGAWG_CAP_repr	GCM1; SPDEF (directAnnotation).
RPL15	transfac_pro__M04893	TAF1 (directAnnotation).
RPL15	transfac_pro__M03876	ZBTB33 (directAnnotation).
RPL15	metacluster_133.1	ZNF304; ZNF304; ZSCAN22 (directAnnotation).
RPL15	transfac_pro__M01219	SP1 (directAnnotation). SP3 (inferredBy_Orthology).
RPL15	metacluster_3.7	SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP3; SP3; SP3; SP4; SP4; SP4; SP4; SP4; SP4; SP5 (directAnnotation).
RPL15	cisbp__M01752	USF2 (inferredBy_Orthology).
RPL15	metacluster_55.5	ZNF541 (directAnnotation).
RPL15	hocomoco__TYY2_HUMAN.H11MO.0.D	YY2 (directAnnotation).
RPL15	metacluster_141.4	GLIS2 (directAnnotation).
RPL15	transfac_pro__M05464	SALL1 (directAnnotation).
RPL15	metacluster_172.23	ZBTB32; ZBTB32 (directAnnotation).
RPL15	taipale__YY2_DBD_NNCCGCCATNW_repr	YY2 (directAnnotation).
RPL15	tfdimers__MD00302	IRF7; IRF8 (directAnnotation).
RPL15	transfac_pro__M06404	ZNF497 (directAnnotation).
RPL15	taipale_tf_pairs__ETV2_HOXB13_NCCGGAAGTYRTAAAN_CAP	ETV2; HOXB13 (directAnnotation).
RPL15	taipale_tf_pairs__HOXD12_ELK3_RSCGGAAGTAATAAAN_CAP	ELK3; HOXD12 (directAnnotation).
RPL15	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	ETS2 (directAnnotation).
RPL15	metacluster_34.4	ETS1; ETS1; ETS1; HCFC1; SIX5; SIX5; SIX5; SIX5; SMARCC2; SMARCC2; THAP11; THAP11; ZNF143; ZNF143; ZNF143; ZNF143 (directAnnotation). TBX2; THAP11; THAP11; ZNF143 (inferredBy_Orthology).
RPL15	transfac_pro__M06331	ZNF343 (directAnnotation).
RPL15	jaspar__MA0748.2	YY2 (directAnnotation).
RPL15	jaspar__MA1460.1	YY1 (inferredBy_Orthology).
RPL15	transfac_pro__M06259	ZNF91 (directAnnotation).
RPL15	hdpi__TIMELESS	TIMELESS (directAnnotation).
RPL15	homer__NANTGCSGCA_Zfp57	ZFP57 (directAnnotation).
RPL15	kznf__ZFP57_Imbeault2017_OM_MEME	ZFP57 (directAnnotation).
RPL15	metacluster_135.10	MBD2; MBD2; MECP2; MECP2 (directAnnotation).
RPL15	metacluster_7.13	ZFX (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
RPL15	"(S)-3-phenyllactic acid"	DB02494	small molecule
RPL15	"Anisomycin"	DB07374	small molecule
RPL15	"Puromycin"	DB08437	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."